Our Team in the News

BioPlan Associates' Ronald Rader

Ron Rader, Sr. Dir. Technical Research: named Editor-in-Chief of Biopharmaceuticals a new peer-reviewed journal from Landes Bioscience. Biopharmaceuticals is the first and only peer-reviewed journal about biopharmaceuticals. Biopharmaceuticals seeks submission of articles concerning biopharmaceuticals and the industry. Please contact the Editor-in-Chief if interested in submitting an article.

BioPlan Associates' Faiz Kermani PhD

Dr Faiz Kermani, Advisory Board: Has helped establish the "Global Health Education Foundation" (GHEF), a not-for-profit healthcare charity to improve educational resources and training for healthcare professionals in developing countries.
At least 1.3 billion people worldwide lack access to the most basic healthcare. The new non-profit foundation, Global Health Education Foundation, aims to tackle such issues. As President of GHEF, Dr Kermani is supporting the R&D focus of the charity to reduce health disparities among developing countries. In particular, the lack of appropriate educational resources and training opportunities for healthcare professionals. http://www.globalhef.org

BioPlan Associates' Managing Director Eric Langer

Eric Langer, Managing Partner: On Advisory Board of “BioProcess Asia Pacific Conference” July 2010 Singapore.
The Biopharmaceutical market in Asia pacific is growing at a rate among the highest in the globe. This is creating a strong need for production of biopharmaceuticals at higher qualities and volumes. Bioprocess AsiaPacific brings together global leaders within biopharmaceutical industry to explore dynamic strategies, benchmark technologies and analyze sustaining the growth of the industry. http://fleminggulf.com/conference/life-science/BioProcessAsiaPacific.


Pricing Effectively

Need help determining whether your pricing is optimizing your profitability?

Let us work with you to maximize your pricing and the value you deliver to your customers. Take advantage of a free 1-hour telephone consultation: Call us today at 301-921-9074.

Pricing is the fastest, single most effective way a company can impact its profitability. Implementing a major marketing and advertising campaign may increase revenue; downsizing may cut costs; reducing manufacturing costs may make you a little more profitable. But effectively managing the price of your products and services will have the fastest impact on your profitability!

Here's a fact: Raise your prices 1% and you will see a 12.3% increase in your product's profitability.*
*(Based on the Standard & Poors 1000 Index, average pricing structure, and cost data. Your pricing structure will differ.)

BioPlan Associates can determine your customers' price sensitivity by market segment.

Benefits of Pricing Right

Effectively manage your product and services pricing:— You will be offering pricing packages and strategies that your competitors can't touch. Deliver real value to your customers.

Get total security in your pricing decisions:—You're pricing and delivering value—based on what your customers demand and expect.

Satisfy yourself, your senior management, and sales team that your price increases are justified: —Because you'll show you're offering real customer value.

Increase your company's overall profitability.e

Pricing strategy should be based on customer value, product mix, your branding strategy, and the quality message you deliver. Life sciences companies, in particular, should design flexibility into their pricing strategies and develop ways to handle the rapid changes and uncertainties in this business segment. Even for technical and novel products, pricing sensitivity analysis is a repeatable and methodical process. Our cost-effective, customer-based approach to pricing analysis gets you the market information you need to leverage this marketing tool and achieve the financial results you expect.

Pricing is an under-managed activity in many companies:

Be sure that your pricing allows for profits. Where is your break even point?

Can you quantify how your product will impact the client's bottom line and return on investment?